Temporal Concept – Talk Bio

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

4 hours ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology

2 days ago talkbio0Tagged AI model, AI-powered, cell classification, Diagnostics, digital pathology, EU, Histopathological aspects, Legal patent, Mindpeak, oncology diagnostics, Pathology, Precision - temporal, Training Programs, United Kingdom, Validation

Mindpeak; digital pathology; AI-powered pathology; oncology diagnostics; cell classification; histopathology; EU patent; United Kingdom validation; AI model training; precision diagnostics

Astrin Biosciences Announces Scientific Advisory Board to Advance Early Cancer Detection Leveraging AI and Proteomics

3 days ago talkbio0Tagged Astrin Biosciences, cancer intelligence, Detection, Liquid Biopsy, Proteomics, Scientific Advisory Board

Astrin Biosciences; Scientific Advisory Board; early cancer detection; AI; proteomics; liquid biopsy; cancer intelligence

AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

3 days ago talkbio0Tagged AstraZeneca, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, AZD0120, BCMAxCD19, CAR-T, China, Clinical Trials, dual-targeting CAR-T, DURGA-1, Frequency of Responses, Multiple Myeloma, Western patients

AstraZeneca; AZD0120; GC012F; dual-targeting CAR-T; BCMAxCD19; multiple myeloma; DURGA-1; China; Western patients; response rate; clinical trial; CAR-T

Bristol Myers Squibb Delays Cobenfy Alzheimer’s Psychosis Trial Readout Due to Site Irregularities

1 week ago talkbio0Tagged ADEPT-2 trial, Alzheimer 's psychosis, Cobenfy, Deferred, Myers Squibb, Phase 3 Clinical Trials, trial site irregularities

Bristol Myers Squibb; Cobenfy; Alzheimer’s psychosis; ADEPT-2 trial; trial site irregularities; Phase III study; delay; 2026

2026 Insmed Summer Internship Program in AI-Based Protein Design

1 week ago talkbio0Tagged AI-Based Protein Design, Computational Biology, Deep Learning, Drug Industry, generative models, Insmed, internship, protein science, Remote Internship, Summer, therapeutic protein

AI-Based Protein Design; Summer Internship; Insmed; Pharmaceutical Industry; Protein Therapeutics; Deep Learning; Computational Biology; Protein Science; Generative Models; Remote Internship

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025

1 week ago talkbio0Tagged central nervous system cancers, Dosage, Escalation, Metastatic Malignant Neoplasm to the Leptomeninges, Phase 1 (qualifier value), Plus Therapeutics, poster spotlight, ReSPECT-LM, REYOBIQ, SABCS, San Antonio Breast Cancer Symposium, Therapeutic radiology procedure

Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics

Generate:Biomedicines Launches Global Phase 3 Trials for AI-Engineered Anti-TSLP Antibody GB-0895 in Severe Asthma

1 week ago talkbio0Tagged AI-engineered antibody, Asthma, Biomedicines, Clinical Trials, GB-0895, Generate, Phase 3, Programmable Biology, Severe (severity modifier), SOLAIRIA-1, SOLAIRIA-2, thymic stromal lymphopoietin, TSLP gene

Generate:Biomedicines; GB-0895; Phase 3 clinical trials; TSLP; thymic stromal lymphopoietin; severe asthma; AI-engineered antibody; programmable biology; SOLAIRIA-1; SOLAIRIA-2

Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027

1 week ago talkbio0Tagged Cardiovascular Diseases, Cereno Scientific, Clinical Development, Directed share, Histone deacetylase inhibitor, Infrequent, Loan, loan financing, milestones, portfolio, Problem, Pulmonary arterial hypertension

Cereno Scientific; SEK 100 million; Directed share issue; SEK 350 million; Loan financing; Q4 2027 milestones; HDAC inhibitor portfolio; Pulmonary arterial hypertension; Clinical development; Rare cardiovascular diseases

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

1 week ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial